Screening for the metabolic side effects of antipsychotic medication: Findings of a 6-year quality improvement programme in the UK

BMJ Open

Volumn 5, Issue 10, 2015, Pages

  Barnes, T R E ^a,b   Bhatti, S F ^b   Adroer, R ^b   Paton, C ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL COLLEGE OF PSYCHIATRISTS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL RECORD; MENTAL HEALTH; MENTAL HEALTH SERVICE; MENTAL PATIENT; METABOLIC SYNDROME X; SECONDARY HEALTH CARE; TOTAL QUALITY MANAGEMENT; UNITED KINGDOM; CHEMICALLY INDUCED; CLINICAL AUDIT; CLINICAL PRACTICE; CLINICAL TRIAL; FOLLOW UP; INCIDENCE; MASS SCREENING; MULTICENTER STUDY; PROCEDURES; PSYCHOTIC DISORDERS; QUESTIONNAIRE; RETROSPECTIVE STUDY; STANDARDS; TIME FACTOR;

ADULT; ANTIPSYCHOTIC AGENTS; CLINICAL AUDIT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MASS SCREENING; MENTAL HEALTH SERVICES; METABOLIC SYNDROME X; PRACTICE PATTERNS, PHYSICIANS'; PSYCHOTIC DISORDERS; QUALITY IMPROVEMENT; RETROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; UNITED KINGDOM;

EID: 84945554801     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-007633     Document Type: Article

References (33)

1. Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol 2014;10:425-48.
2. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123-31.
3. Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 2012;25:83-8.
4. Berrocal-Izquierdo N, Bernardo M. Schizophrenia and cerebrovascular disease. A description of a series and bibliographic review. Actas Esp Psiquiatr 2014;42:74-82.
5. Vancampfort D, Wampers M, Mitchell AJ, et al. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013;12:240-50.
6. Malhotra N, Kulhara P, Chakrabarti S, et al. A prospective, longitudinal study of metabolic syndrome in patients with bipolar disorder and schizophrenia. J Affect Disord 2013;150:653-8.
7. Suttajit S, Pilakanta S. Prevalence of metabolic syndrome and its association with depression in patients with schizophrenia. Neuropsychiatr Dis Treat 2013;9:941-6.
8. Morgan VA, McGrath JJ, Jablensky A, et al. Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. Psychol Med 2014;44:2163-76.
9. National Institute for Health and Clinical Excellence. Managing overweight and obesity in adults - lifestyle weight management services. NICE Public Health Guidance 53, 2014.
10. Newcomer JW, Weiden PJ, Buchanan RW. Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. J Clin Psychiatry 2013;74:1108-20.
11. Fan X, Borba CP, Copeland P, et al. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand 2013;127:217-26.
12. Wang LJ, Ree SC, Huang YS, et al. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 2013;40:260-6.
13. Mizuno Y, Suzuki1 T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2014;4:1385-403.
14. Barnes TRE, Paton C, Cavanagh M, et al. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull 2007;33:1397-403.
15. Mitchell AJ, Delaffon V, Vancampfort D, et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 2012;42:125-47.
16. Barnes TRE, Paton C. Improving prescribing practice in psychiatry: the experience of the Prescribing Observatory for Mental Health (POMH-UK). Int Rev Psychiatry 2011;23:328-35.
17. Joint Formulary Committee. British National Formulary (edition 68). London: BMJ Group and Pharmaceutical Press, 2014.
18. National Institute for Health and Clinical Excellence. Psychosis and schizophrenia in adults: treatment and management. NICE Clinical Guideline 178, 2014.
19. Barnes TRE, Paton C, Hancock E, et al. UK Prescribing Observatory for Mental Health. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr Scand 2008;118:26-33.
20. Gumber R, Abbas M, Minajagi M. Monitoring the metabolic side-effects of atypical antipsychotics. Psychiatr Bull 2010;34:390-5.
21. SEPT quality account 2010-11. South Essex Partnership University NHS Foundation Trust, 2011.
22. Reddy HT, Edwards R. Screening of metabolic side effects of antipsychotics in patients with mental disorder (abstract 4P03-105). Eur Psychiatry 2011;26(Supplement 1):1274.
23. Clinical Audit Project Abstract MH 446 12 13. POMH-UK Audit Topic 2f: screening for metabolic side effects of antipsychotic drugs. South Staffordshire & Shropshire Healthcare NHS Foundation Trust, 2012.
24. Najim H. Monitoring cardiometabolic risk in schizophrenia. Br J Psychiatry 2012;201:75-6.
25. Quality Report 2012-2013. Humber NHS Foundation Trust, 2013. 21.
26. Oxleas NHS. Quality Report 2012-2013, Improving Lives. Oxleas NHS Foundation Trust, 2013.
27. National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. NICE Clinical Guideline 1, 2002.
28. National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. NICE Clinical Guideline 82, 2009.
29. Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines, 8th edition. London and New York: Taylor & Francis, 2005.
30. National Institute for Health and Clinical Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE Clinical Guideline 67, 2008.
31. Royal College of Psychiatrists. Physical health in mental health: final report of a scoping group. Occasional Paper OP67. January 2009.
32. Kristensen SR, McDonald R, Sutton M. Should pay-for-performance schemes be locally designed? Evidence from the Commissioning for Quality and Innovation (CQUIN) framework. J Health Serv Res Policy 2013;18(Suppl. 2):38-49.
33. Lester H, Campbell S. Developing quality and outcome framework (QOF) indicators and the concept of 'QOF ability'. Qual Prim Care 2010;18:103-9.